Zimmer Biomet Holdings (NYSE:ZBH) reported Q1 EPS of $1.61, $0.20 better than the analyst estimate of $1.41. Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.59 billion.
GUIDANCE:
Zimmer Biomet Holdings sees FY2022 EPS of $6.65-$6.85, versus prior guidance of $6.40-$6.80 and the consensus of $6.54. The company sees revenue down 1.5% to up 0.5%, versus prior of down 4% to flat.